NO20022557D0 - 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler - Google Patents

2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler

Info

Publication number
NO20022557D0
NO20022557D0 NO20022557A NO20022557A NO20022557D0 NO 20022557 D0 NO20022557 D0 NO 20022557D0 NO 20022557 A NO20022557 A NO 20022557A NO 20022557 A NO20022557 A NO 20022557A NO 20022557 D0 NO20022557 D0 NO 20022557D0
Authority
NO
Norway
Prior art keywords
immunosuppressants
compounds useful
diaminopyrimidine compounds
diaminopyrimidine
useful
Prior art date
Application number
NO20022557A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022557L (no
Inventor
Todd Andrew Blumenkopf
Eileen Elliott Mueller
Eric Jan Roskamp
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20022557D0 publication Critical patent/NO20022557D0/no
Publication of NO20022557L publication Critical patent/NO20022557L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
NO20022557A 1999-11-30 2002-05-29 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler NO20022557L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30
PCT/IB2000/001628 WO2001040215A1 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds usful as immunosuppressants

Publications (2)

Publication Number Publication Date
NO20022557D0 true NO20022557D0 (no) 2002-05-29
NO20022557L NO20022557L (no) 2002-05-29

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022557A NO20022557L (no) 1999-11-30 2002-05-29 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler

Country Status (33)

Country Link
EP (1) EP1242403B1 (ja)
JP (1) JP3955468B2 (ja)
KR (1) KR20020059826A (ja)
CN (1) CN1402720A (ja)
AP (1) AP2002002530A0 (ja)
AT (1) ATE315036T1 (ja)
AU (1) AU1047601A (ja)
BG (1) BG106695A (ja)
BR (1) BR0015995A (ja)
CA (1) CA2392971C (ja)
CO (1) CO5261519A1 (ja)
CZ (1) CZ20021703A3 (ja)
DE (1) DE60025385T2 (ja)
EA (1) EA200200411A1 (ja)
EE (1) EE200200275A (ja)
ES (1) ES2253266T3 (ja)
GT (1) GT200000200A (ja)
HN (1) HN2000000264A (ja)
HU (1) HUP0203300A3 (ja)
IL (1) IL149103A0 (ja)
IS (1) IS6339A (ja)
MA (1) MA26846A1 (ja)
MX (1) MXPA02005350A (ja)
NO (1) NO20022557L (ja)
OA (1) OA12097A (ja)
PA (1) PA8506801A1 (ja)
PE (1) PE20010900A1 (ja)
PL (1) PL355946A1 (ja)
SV (1) SV2002000231A (ja)
TN (1) TNSN00232A1 (ja)
TR (1) TR200201431T2 (ja)
UY (1) UY26455A1 (ja)
WO (1) WO2001040215A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1429222A (zh) * 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
AP2001002266A0 (en) * 2000-08-31 2001-09-30 Pfizer Prod Inc Pyrazole derivatives.
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CN101037438A (zh) 2002-08-02 2007-09-19 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
JP2007517831A (ja) * 2004-01-16 2007-07-05 ノバルティス アクチエンゲゼルシャフト ２，４−ジアミノピリミジンおよび心筋再生を誘起するためのその使用
JP2008515980A (ja) * 2004-10-12 2008-05-15 デコード ジェネティクス イーエイチエフ 閉塞性動脈疾患のためのアリールスルホンアミドぺリ置換二環式化合物
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007095188A2 (en) 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
BRPI0710181A2 (pt) * 2006-03-16 2011-08-09 Novartis Ag compostos orgánicos
JP2010526825A (ja) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
KR101536021B1 (ko) * 2007-10-16 2015-07-10 다이이찌 산쿄 가부시키가이샤 피리미딜 인돌린 화합물
BR112012006652A2 (pt) 2009-09-25 2015-09-08 Vertex Pharma métodos para preparar os derivados de pirimidina úteis como inibidores de proteína cinase
SG179207A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
JP7039802B2 (ja) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
CN117343049A (zh) * 2017-06-30 2024-01-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110573501B (zh) * 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
DE60025385T2 (de) 2006-08-24
OA12097A (en) 2006-05-04
JP3955468B2 (ja) 2007-08-08
EA200200411A1 (ru) 2002-10-31
DE60025385D1 (de) 2006-03-30
TR200201431T2 (tr) 2002-09-23
SV2002000231A (es) 2002-07-16
HN2000000264A (es) 2001-05-21
IS6339A (is) 2002-04-12
ES2253266T3 (es) 2006-06-01
AU1047601A (en) 2001-06-12
KR20020059826A (ko) 2002-07-13
TNSN00232A1 (fr) 2005-11-10
EP1242403B1 (en) 2006-01-04
WO2001040215A1 (en) 2001-06-07
CZ20021703A3 (cs) 2003-06-18
CA2392971C (en) 2008-10-07
UY26455A1 (es) 2001-07-31
PL355946A1 (en) 2004-05-31
CA2392971A1 (en) 2001-06-07
BR0015995A (pt) 2002-08-06
PA8506801A1 (es) 2002-04-25
MXPA02005350A (es) 2002-12-11
CO5261519A1 (es) 2003-03-31
ATE315036T1 (de) 2006-02-15
EE200200275A (et) 2003-10-15
EP1242403A1 (en) 2002-09-25
JP2003515602A (ja) 2003-05-07
GT200000200A (es) 2002-05-23
BG106695A (bg) 2002-12-29
MA26846A1 (fr) 2004-12-20
HUP0203300A2 (hu) 2003-02-28
NO20022557L (no) 2002-05-29
IL149103A0 (en) 2002-11-10
AP2002002530A0 (en) 2002-06-30
PE20010900A1 (es) 2001-09-08
CN1402720A (zh) 2003-03-12
HUP0203300A3 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
NO20022557D0 (no) 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
NO20024153D0 (no) 2,4-Di(hetero-)arylamino(-oksy)-5-substituerte pyrimidiner som antineoplastiske midler
AP2002002529A0 (en) 2,4-Diaminopyrimidine compounds useful as immunosupressants
ID27595A (id) SENYAWA-SENYAWA PIROLO (2,3-d) PIRIMIDINA
NO20012701D0 (no) Aryl- og heterosyklylsubstituerte pyrimidinderivater som antikoagulanter
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
ITTO20000976A0 (it) Composizioni acaricide.
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
NO20011738L (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
PT1210349E (pt) Pirazolo-¬4,3-d|-pirimidinas
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
DE69900626D1 (de) Abgleichbare, frequenzstabilisierende, chipinterne kondensatoranordnung
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
IT1308639B1 (it) Composti triazinici fluorurati.
DK1075471T3 (da) Idolylderivater som serotonerge midler
NO20034529L (no) 3,7-diazabicyklo(3,3,1) - formuleringer som anti-arytmi- forbindelser
IT1313594B1 (it) Bisplatino complessi attivi per via orale.
DK1380585T3 (da) Pyrazolopyridinon som mellemprodukt
NO20013640D0 (no) 3,6-disubstituerte penamsufon-derivater som antibakterielle midler
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application